Luminespib (NVP-AUY922)

Name: Luminespib (NVP-AUY922)
Brand: Selleck Chemicals
SKU: S1069
Rating: 5 (67 reviews)

For research use only.

Catalog No.S1069 Synonyms: AUY-922

67 publications

Luminespib (NVP-AUY922) Chemical Structure

Molecular Weight(MW): 465.54

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Luminespib (AUY-922, NVP-AUY922) effectively downregulates and destabilizes the IGF-1Rβ protein and results in growth inhibition, autophagy and apoptosis. Phase 2.

Selleck's Luminespib (NVP-AUY922) has been cited by 67 publications

Cancer Cell, 2020, 37(3):371-386

PubMed: 32109374 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cell, 2012, 31;150(5):987-1001.

PubMed: 22939624 ( click the link to review the publication )

Nat Commun, 2020, 11(1):562

PubMed: 31992715 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(13):E4740

PubMed: 32635192 ( click the link to review the publication )

Int J Mol Med, 2020, 45(5):1543-1553

PubMed: 32323753 ( click the link to review the publication )

Exp Lung Res, 2020, 46(6):203-216

PubMed: 32400213 ( click the link to review the publication )

Korean J Physiol Pharmacol, 2020, 1;24(3):241-248

PubMed: 32395075 ( click the link to review the publication )

Nat Commun, 2019, 10(1):402

PubMed: 30679438 ( click the link to review the publication )

J Neurosci, 2019, 39(17):3332-3344

PubMed: 30696728 ( click the link to review the publication )

Cells, 2019, 8(8)

PubMed: 31370342 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):2097-2110

PubMed: 31395684 ( click the link to review the publication )

Front Endocrinol (Lausanne), 2019, 10:487

PubMed: 31379752 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):102

PubMed: 30678647 ( click the link to review the publication )

Clin Exp Med, 2019, 10.1007/s10238-019-00587-2

PubMed: 31650359 ( click the link to review the publication )

Hepatology, 2019, 69(2):573-586

PubMed: 29356025 ( click the link to review the publication )

ACS Chem Neurosci, 2019, 10(6):2890-2902

PubMed: 31017387 ( click the link to review the publication )

Transl Lung Cancer Res, 2019, 8(4):340-351

PubMed: 31555510 ( click the link to review the publication )

Autophagy, 2018, 14(6):958-971

PubMed: 29561705 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6548-6555

PubMed: 30154228 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(3):e7858

PubMed: 29507054 ( click the link to review the publication )
J Cell Mol Med, 2018, 22(3):1792-1804

PubMed: 29363851 ( click the link to review the publication )

BMB Rep, 2018, 51(12):660-665

PubMed: 30591093 ( click the link to review the publication )

Cancer Lett, 2017, 411:19-26

PubMed: 28987383 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2017, 80(4):673-684

PubMed: 28779264 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 487(2):313-319

PubMed: 28412368 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:2219-2226

PubMed: 28458565 ( click the link to review the publication )

Sci Rep, 2017, 7(1):201

PubMed: 28298630 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Cancer Lett, 2016, 372(1):75-81

PubMed: 26723875 ( click the link to review the publication )

Sci Rep, 2016, 6:33710

PubMed: 27641368 ( click the link to review the publication )

J Biol Chem, 2016, 291(19):10332-46

PubMed: 26957545 ( click the link to review the publication )

Horm Cancer, 2016, 7(2):114-26

PubMed: 26858237 ( click the link to review the publication )

PeerJ, 2016, 4:e1683

PubMed: 26893968 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

Oncotarget, 2016, 7(31):49597-49610

PubMed: 27391062 ( click the link to review the publication )

Immun Inflamm Dis, 2016, 4(4):463-473

PubMed: 27980780 ( click the link to review the publication )

PLoS Negl Trop Dis, 2015, 8(2):e2699

PubMed: 24551261 ( click the link to review the publication )

Biochimica et Biophysica Acta, 2015, 10.1016/j.bbamcr.2015.05.012

PubMed: 25982393 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2015, 309(12):L1410-9

PubMed: 26498249 ( click the link to review the publication )

Int J Biol Sci, 2015, 11(8):923-34

PubMed: 26157347 ( click the link to review the publication )

Molecules, 2015, 20(1):1643-60

PubMed: 25608045 ( click the link to review the publication )

Biochemistry, 2015, 10.1021/acs.biochem.5b00148

PubMed: 25905789 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0119832

PubMed: 25780909 ( click the link to review the publication )

Oncol Lett, 2015, 10(2):941-945

PubMed: 26622600 ( click the link to review the publication )
Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Oncoscience, 2015, 2(4):419-427

PubMed: 26097875 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(15):E1528-37

PubMed: 24706778 ( click the link to review the publication )

Int J Cancer, 2014, 135(10):2462-74

PubMed: 24706460 ( click the link to review the publication )

PLoS Negl Trop Dis, 2014, 8(2):e2699

PubMed: 24551261 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2014, 50(1):170-9

PubMed: 23972231 ( click the link to review the publication )

Cell Signal, 2014, 27(2):293-305

PubMed: 25446253 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114506

PubMed: 25503774 ( click the link to review the publication )

Tumour Biol, 2014, 35(8):8193-9

PubMed: 24850175 ( click the link to review the publication )

Mol Oncol, 2013, 7(6):1093-102

PubMed: 23993685 ( click the link to review the publication )

J Biol Chem, 2013, 288(23):16308-20

PubMed: 23599433 ( click the link to review the publication )

J Proteome Res, 2013, 12(8):3697-706

PubMed: 23763277 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 273(2):401-9

PubMed: 24090817 ( click the link to review the publication )

PLoS Pathog, 2012, 8(11):e1003048

PubMed: 23209418 ( click the link to review the publication )

Br J Haematol, 2012, 160(4):465-76

PubMed: 23252346 ( click the link to review the publication )

Mol Cell Biochem, 2012, 370(1-2):141-50

PubMed: 22865466 ( click the link to review the publication )

American Society of Clinical Oncology Annual Meeting, 2012, Chicago

PubMed: ( click the link to review the publication )

Mol Cancer, 2011, 10:125

PubMed: 21962244 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HSP (HSP90) Inhibitors

Biological Activity

Description

Targets

HSP90α ^[1] (Cell-free assay)	HSP90β ^[1] (Cell-free assay)
13 nM	21 nM

In vitro

NVP-AUY922 inhibits proliferation of various human cancer cell lines in vitro, with an average GI50 of 9 nM. ^[1] The IC50 values of NVP-AUY922 fall in the range of 2 to 40 nM in these gastric cancer cell lines. IC50 value for the BEAS-2B cells is 28.49 nM. Treatment with NVP-AUY922 does not influence the expression of HSP90, but expression of HSP70 gets elevated by NVP-AUY922 treatment. NVP-AUY922 increases the binding of HSP70 to HSP90. NVP-AUY922 causes p23 dissociation from the HSP90 complex and can then recruit HSP70 to the HSP90 complex. ^[1] After the treatment with NVP-AUY922, expression of receptor tyrosine kinases including VEGFR1, 2, 3 and PDGFRɑ is decreased. A decrease is also noticed in the expression of Akt and phospho-Akt. Meanwhile, treatment with NVP-AUY922 causes decreased expression of HER-2 in NCI-N87 cells. NVP-AUY922 treatment results in binding of HSP90 to client proteins and setting them up as targets for degradation by the proteasome. NVP-AUY922 can influence cell growth by affecting multiple signaling pathways. In addition, treatment with the proteasome inhibitor, MG132, restores expression of thymidylate synthase, which is decreased by NVP-AUY922. NVP-AUY922 increases the expression of cleaved caspase-3 leading to apoptosis in HSC-2 cells.^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
CMK	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTBwMECwNVI2KM7:TR?=	MULTRW5ITVJ?
MV-4-11	MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml76TWM2OD1yLkCwNFU2QCEQvF2=	Mm\UV2FPT0WU
NALM-6	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXUS4J5UUN3ME2wMlAxODh2MjFOwG0>	M2O4bXNCVkeHUh?=
HOS	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DsZmlEPTB;MD6wNFE{QCEQvF2=	MkD1V2FPT0WU
HT-144	MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HGeWlEPTB;MD6wNFE2PSEQvF2=	MkO2V2FPT0WU
SW1710	M4[4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Pv[GlEPTB;MD6wNFE5PiEQvF2=	M1zYPXNCVkeHUh?=
TE-8	NYK1UFQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3pOnJKSzVyPUCuNFAzOzdizszN	M3jTfXNCVkeHUh?=
ES1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rTPGlEPTB;MD6wNFI3PiEQvF2=	NVTTVm85W0GQR1XS
CCF-STTG1	NH3EXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwMECyPVch\|ryP	NUK0SZVoW0GQR1XS
PSN1	NF\1WnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;mTWM2OD1yLkCwN\|E5KM7:TR?=	MV3TRW5ITVJ?
CAL-51	M1fVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwMECzNlUh\|ryP	MV7TRW5ITVJ?
MCF7	NILod\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7FdnRyUUN3ME2wMlAxOzN3IN88US=>	MXXTRW5ITVJ?
SK-HEP-1	NWDNdW1mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjnWJIyUUN3ME2wMlAxOzN4IN88US=>	NHjOb25USU6JRWK=
LCLC-103H	NGHOVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jL[WlEPTB;MD6wNFQ{KM7:TR?=	M3viWXNCVkeHUh?=
HMV-II	Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXK1PFRqUUN3ME2wMlAxPDR7IN88US=>	M1XTRXNCVkeHUh?=
MES-SA	MlLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1v5WWlEPTB;MD6wNFQ2OiEQvF2=	M2nWcnNCVkeHUh?=
SK-LMS-1	Mm\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU[xbldMUUN3ME2wMlAxPDV6IN88US=>	NH;vSpFUSU6JRWK=
639-V	Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\WWGlEPTB;MD6wNFQ5PSEQvF2=	M1fnXXNCVkeHUh?=
SIG-M5	NYDRZWhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwMEC0PFkh\|ryP	MXXTRW5ITVJ?
LOUCY	NVTtbJA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwMEC1NFUh\|ryP	MkLHV2FPT0WU
HSC-2	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjoUpJzUUN3ME2wMlAxPTF6IN88US=>	NUDRcmpPW0GQR1XS
EW-13	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTBwMEC1NVgh\|ryP	M2S4SHNCVkeHUh?=
RT-112	NVWyfIdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnWNoNbUUN3ME2wMlAxPTN3IN88US=>	Ml;MV2FPT0WU
NKM-1	Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHaN3NKSzVyPUCuNFA2PDdizszN	MlzXV2FPT0WU
KYSE-180	NH\pbFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XIVWlEPTB;MD6wNFU5PiEQvF2=	NH7vU\|ZUSU6JRWK=
SW1783	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLvU4ZzUUN3ME2wMlAxPTlzIN88US=>	NH;GXo9USU6JRWK=
A431	NIPocWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfhXJEyUUN3ME2wMlAxPjB5IN88US=>	MVHTRW5ITVJ?
SK-OV-3	NUjEdI9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwMEC2N{DPxE1?	NEHt[VNUSU6JRWK=
RPMI-7951	NICyWIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwMEC2N\|Eh\|ryP	MX;TRW5ITVJ?
Capan-2	NGXiSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHz0TnRKSzVyPUCuNFA3OzhizszN	NXzGTnRZW0GQR1XS
HSC-3	NXjUcHV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLkTWM2OD1yLkCwOlQyKM7:TR?=	MoruV2FPT0WU
786-0	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPmR\|Y3UUN3ME2wMlAxPjZ\|IN88US=>	NUTOW4FOW0GQR1XS
Daoy	NFq1[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvtfJlKSzVyPUCuNFA3QTVizszN	NWnwfFFJW0GQR1XS
KGN	M3rHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17wRmlEPTB;MD6wNFcxOyEQvF2=	NFXHTVhUSU6JRWK=
EW-16	M3HhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTBwMEC3OFkh\|ryP	M2PCUnNCVkeHUh?=
EW-7	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;TZWlEPTB;MD6wNFc2PCEQvF2=	Mlv4V2FPT0WU
IGROV-1	M3vIN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnnTWM2OD1yLkCwPFE1KM7:TR?=	NVLjNXNEW0GQR1XS
8505C	MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTBwMEC4NlEh\|ryP	MlPRV2FPT0WU
RKO	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PwXmlEPTB;MD6wNFgzPiEQvF2=	M37FdHNCVkeHUh?=
GDM-1	M4H0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTBwMEC4OEDPxE1?	M3nhcXNCVkeHUh?=
IST-MEL1	NUPRdY1vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTBwMEC4OVIh\|ryP	MnHZV2FPT0WU
RPMI-6666	MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTXR4hKUUN3ME2wMlAxQDV{IN88US=>	NYnDOog{W0GQR1XS
SNG-M	M4\RUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrwdmZrUUN3ME2wMlAxQDV4IN88US=>	MU\TRW5ITVJ?
KS-1	MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPDTWM2OD1yLkCwPFU6KM7:TR?=	MWLTRW5ITVJ?
RXF393	Ml7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXDb4FKSzVyPUCuNFA5PiEQvF2=	NGfRTJRUSU6JRWK=
CAL-12T	NY\zOmtDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fEXmlEPTB;MD6wNFkzOiEQvF2=	MmnSV2FPT0WU
BFTC-905	NH\iV5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPURpNWUUN3ME2wMlAxQTN6IN88US=>	MmjwV2FPT0WU
SK-MES-1	NYi5NWlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmr0TWM2OD1yLkCwPVQ2KM7:TR?=	NYLpdHZQW0GQR1XS
BB30-HNC	NF\oelJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7DZpBKSzVyPUCuNFA6PTJizszN	NF;FTY1USU6JRWK=
AN3-CA	M1jue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfvdnhKSzVyPUCuNFExOTdizszN	NGrSUI1USU6JRWK=
EFO-27	NVnIclVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVi3bJdDUUN3ME2wMlAyODF5IN88US=>	M3nxU3NCVkeHUh?=
G-401	Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{[2SGlEPTB;MD6wNVAzPSEQvF2=	MnryV2FPT0WU
BPH-1	NEPLWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTBwMEGwN{DPxE1?	M3TyNnNCVkeHUh?=
NCI-H727	Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwMEGwN{DPxE1?	Mn\tV2FPT0WU
SNU-423	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjWcVJKSzVyPUCuNFExPTNizszN	NGnVfIpUSU6JRWK=
KYSE-270	NGrBSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\YdWhKSzVyPUCuNFExPTlizszN	MmnoV2FPT0WU
AGS	MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPKOJBKSzVyPUCuNFExPjFizszN	MkO1V2FPT0WU
NCI-H2228	NHLpbZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4P2emlEPTB;MD6wNVA3PCEQvF2=	NXntd403W0GQR1XS
SW954	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\TNmloUUN3ME2wMlAyODdzIN88US=>	MlHKV2FPT0WU
769-P	MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzsZ2RHUUN3ME2wMlAyODd\|IN88US=>	MXHTRW5ITVJ?
BB49-HNC	MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonGTWM2OD1yLkCxNFc4KM7:TR?=	NYjtR\|dpW0GQR1XS
IA-LM	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwMEGwPFYh\|ryP	NVP6PZR1W0GQR1XS
NB69	Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nqdWlEPTB;MD6wNVExOiEQvF2=	MWjTRW5ITVJ?
C8166	M{\ETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1P4OmlEPTB;MD6wNVEzQSEQvF2=	NGrWR\|JUSU6JRWK=
NCI-H1299	NEXse5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTBwMEGxOVQh\|ryP	NYjNTHhbW0GQR1XS
YKG-1	M2jYT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTBwMEGxOkDPxE1?	MVXTRW5ITVJ?
PANC-03-27	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fOSWlEPTB;MD6wNVE3OiEQvF2=	NVGzZnZRW0GQR1XS
YT	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7WS5hKSzVyPUCuNFEyPzlizszN	MlHKV2FPT0WU
CAL-85-1	NWjOd5dyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\xSHVEUUN3ME2wMlAyOTl{IN88US=>	NGn6PHhUSU6JRWK=
GT3TKB	NFribGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPNTWM2OD1yLkCxNlAzKM7:TR?=	M364enNCVkeHUh?=
BB65-RCC	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjjXW9KSzVyPUCuNFEzODRizszN	M4nNVHNCVkeHUh?=
ES6	MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDNeXhKSzVyPUCuNFEzPjFizszN	MXPTRW5ITVJ?
MHH-ES-1	NGDhSZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFr2[2JKSzVyPUCuNFEzPjNizszN	MXzTRW5ITVJ?
QIMR-WIL	MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwMEGyOlkh\|ryP	MVXTRW5ITVJ?
SNU-C2B	M4O3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\y[XBKSzVyPUCuNFEzPzJizszN	NWLIdJN5W0GQR1XS
OCI-AML2	NWPXeVhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMEGyPFEh\|ryP	NX\2PIZrW0GQR1XS
DU-145	MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{O0UmlEPTB;MD6wNVI6KM7:TR?=	NFOxO3hUSU6JRWK=
SW982	M{HQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTBwMEGyPVMh\|ryP	M1;RWHNCVkeHUh?=
MFH-ino	M{XKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwMEGyPVMh\|ryP	NVr1[2RuW0GQR1XS
A427	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\XZmlEPTB;MD6wNVI6QSEQvF2=	NHr4OnNUSU6JRWK=
LCLC-97TM1	NHvtXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHQTWM2OD1yLkCxN{DPxE1?	MkHSV2FPT0WU
AM-38	NF;UTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTBwMEGzNFIh\|ryP	Mk\EV2FPT0WU
K5	MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwMEGzNFgh\|ryP	NGnRZ2hUSU6JRWK=
T84	NIXxcZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoX1TWM2OD1yLkCxN\|MyKM7:TR?=	M1fifXNCVkeHUh?=
TE-15	M4X3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXiTWM2OD1yLkCxN\|M3KM7:TR?=	MkTZV2FPT0WU
NCI-H460	NVP4fFBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwMEGzN\|Yh\|ryP	NU\zPFA1W0GQR1XS
NTERA-S-cl-D1	MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\QTWlEPTB;MD6wNVM{QSEQvF2=	MYHTRW5ITVJ?
KYSE-450	MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFT2ZZRKSzVyPUCuNFE{PDlizszN	MlSzV2FPT0WU
H4	Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrONog1UUN3ME2wMlAyOzZ4IN88US=>	NFnPZYFUSU6JRWK=
LC-2-ad	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPET5pGUUN3ME2wMlAyOzdizszN	NYm5ZXZiW0GQR1XS
GAMG	NXjEOmxqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGe5RnZKSzVyPUCuNFE{PzFizszN	MnnKV2FPT0WU
TK10	NFXBcYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfMNZRKSzVyPUCuNFE{QDJizszN	NXX0U3R{W0GQR1XS
NCI-H2122	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGn2emZKSzVyPUCuNFE{QDRizszN	M4fKR3NCVkeHUh?=
KM12	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPMS2F2UUN3ME2wMlAyOzl7IN88US=>	MVHTRW5ITVJ?
CAL-39	MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEm3dIZKSzVyPUCuNFE1OiEQvF2=	M1u1VXNCVkeHUh?=
RPMI-2650	NGfsXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXLTWM2OD1yLkCxOFMzKM7:TR?=	M2rP[XNCVkeHUh?=
KYSE-510	M2e1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHYTWM2OD1yLkCxOFQzKM7:TR?=	MWDTRW5ITVJ?
KALS-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTBwMEG0OlYh\|ryP	Mo\qV2FPT0WU
NCI-H1648	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17jTWlEPTB;MD6wNVQ6QSEQvF2=	M161WnNCVkeHUh?=
ES4	M4ryeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTUcopKSzVyPUCuNFE2ODJizszN	MYjTRW5ITVJ?
C-33-A	M3TMbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTBwMEG1NFkh\|ryP	NIHycWdUSU6JRWK=
MIA-PaCa-2	MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPrNlFVUUN3ME2wMlAyPTB7IN88US=>	MlHmV2FPT0WU
Becker	M2\S[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml34TWM2OD1yLkCxOVE1KM7:TR?=	MVXTRW5ITVJ?
HOP-62	M13JW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFe2fZhKSzVyPUCuNFE2PDJizszN	NFftSHNUSU6JRWK=
TE-1	Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrRUGxCUUN3ME2wMlAyPThzIN88US=>	NGP4bJRUSU6JRWK=
KYSE-410	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3f6PWlEPTB;MD6wNVU5PiEQvF2=	MXzTRW5ITVJ?
NOS-1	M33UUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLpXI9KSzVyPUCuNFE2QTNizszN	NWL6bWk{W0GQR1XS
MEL-HO	Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwMEG2OFMh\|ryP	MoXjV2FPT0WU
NCI-H1650	M3XzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTpZXNzUUN3ME2wMlAyPjR4IN88US=>	NYXZ[GhWW0GQR1XS
VMRC-RCZ	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nzeGlEPTB;MD6wNVY2OSEQvF2=	NYPPeWhYW0GQR1XS
HuP-T3	M{nafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjmR2psUUN3ME2wMlAyPjV\|IN88US=>	M{nhT3NCVkeHUh?=
ACN	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LJbGlEPTB;MD6wNVY2PyEQvF2=	NFSwNmxUSU6JRWK=
MEL-JUSO	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmC3TWM2OD1yLkCxOlgyKM7:TR?=	Mkj6V2FPT0WU
HT-1197	M4XZOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwMEG2PFUh\|ryP	NX\ZRnVwW0GQR1XS
NCI-H2030	NUTsTGc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTBwMEG2PVch\|ryP	M13ZNXNCVkeHUh?=
A4-Fuk	NFnNco1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7yWVhKSzVyPUCuNFE4ODJizszN	NYS5VmlpW0GQR1XS
NCI-H292	Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLTTWM2OD1yLkCxO\|A6KM7:TR?=	NGiyXJdUSU6JRWK=
A2780	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\mU2lEPTB;MD6wNVcyPSEQvF2=	NGnK[WVUSU6JRWK=
SF295	NEP2R\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPLcWZjUUN3ME2wMlAyPzJzIN88US=>	NHLjfFVUSU6JRWK=
NCI-H810	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHzUGhKSzVyPUCuNFE4OjRizszN	NWDBb4hqW0GQR1XS
ALL-PO	NY\wO4F2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlH1TWM2OD1yLkCxO\|M2KM7:TR?=	M2O1W3NCVkeHUh?=
MC-IXC	NXfmU2dqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwMEG3N\|Yh\|ryP	NVe2TWRWW0GQR1XS
NY	NFTueZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwMEG3OEDPxE1?	NHqxXnJUSU6JRWK=
OMC-1	M2LrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jmTmlEPTB;MD6wNVc2OSEQvF2=	MWnTRW5ITVJ?
PANC-10-05	NVPFXW1IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIH2dHFKSzVyPUCuNFE4PTVizszN	NHrNbIJUSU6JRWK=
NCI-H2342	Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{m1NGlEPTB;MD6wNVc2QCEQvF2=	M4\KfnNCVkeHUh?=
HGC-27	MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\6bWpzUUN3ME2wMlAyPzV6IN88US=>	NF2x[I9USU6JRWK=
TE-12	MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\3TJBKSzVyPUCuNFE4PzVizszN	M4GyU3NCVkeHUh?=
MOLT-16	NE[3TmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M16yNGlEPTB;MD6wNVc5QCEQvF2=	NUTFOmRtW0GQR1XS
HL-60	MkOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPNUXpKSzVyPUCuNFE5ODdizszN	NWH6TXZtW0GQR1XS
OVCAR-5	M4nQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTBwMEG4NVIh\|ryP	NXvQdmJVW0GQR1XS
SK-LU-1	NYG4XpZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml[3TWM2OD1yLkCxPFQ3KM7:TR?=	M17HZnNCVkeHUh?=
MG-63	MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfYSWNCUUN3ME2wMlAyQDd2IN88US=>	NILWfndUSU6JRWK=
8-MG-BA	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXz3dXNuUUN3ME2wMlAyQDh2IN88US=>	MV7TRW5ITVJ?
COR-L105	NFrwcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTBwMEG5NVEh\|ryP	M37VbXNCVkeHUh?=
BHY	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIi5SHBKSzVyPUCuNFE6OTJizszN	NV\adHhLW0GQR1XS
SW620	M1S4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HPdmlEPTB;MD6wNVkyPSEQvF2=	NVmydYRkW0GQR1XS
PC-14	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7Eb\|BGUUN3ME2wMlAyQTN2IN88US=>	MWXTRW5ITVJ?
NCI-H522	NWHIVJBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XNPWlEPTB;MD6wNVk{QSEQvF2=	NYSz[XduW0GQR1XS
OE19	M2nqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLDPJhKSzVyPUCuNFE6PSEQvF2=	MmDWV2FPT0WU
RVH-421	NXz1TW44T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfFdFNKSzVyPUCuNFE6PTdizszN	MXHTRW5ITVJ?
TE-10	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIj1Z5JKSzVyPUCuNFE6PzdizszN	MnGzV2FPT0WU
A101D	NF;QT2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rmfmlEPTB;MD6wNVk5PyEQvF2=	Ml:yV2FPT0WU
HUTU-80	NHfSbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTBwMEKwNFQh\|ryP	Ml;pV2FPT0WU
KYSE-140	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXQUYlKSzVyPUCuNFIxOjRizszN	MmO4V2FPT0WU
SNU-449	M1vDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfqTWM2OD1yLkCyNFI3KM7:TR?=	M4TMdXNCVkeHUh?=
697	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LhUGlEPTB;MD6wNlA{OSEQvF2=	MYTTRW5ITVJ?
SJSA-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTBwMEKwN\|ch\|ryP	NITQZXlUSU6JRWK=
IGR-1	NYnH[4ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnS1TWM2OD1yLkCyNFUh\|ryP	MVvTRW5ITVJ?
GCIY	NVLUXmIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{j4e2lEPTB;MD6wNlA2PSEQvF2=	M2\1[XNCVkeHUh?=
REH	NFnpWVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmH2TWM2OD1yLkCyNFU6KM7:TR?=	MWDTRW5ITVJ?
A204	NWjId2RyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHO2Wo1KSzVyPUCuNFIyOTVizszN	MYTTRW5ITVJ?
A388	MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwMEKxNVUh\|ryP	M3rtWXNCVkeHUh?=
NCI-H650	NGi2fo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHn0[FhKSzVyPUCuNFIyOTdizszN	NXrmboxvW0GQR1XS
SW626	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\m[3NKSzVyPUCuNFIyOiEQvF2=	M3G4NXNCVkeHUh?=
DoTc2-4510	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4H3VWlEPTB;MD6wNlEzOiEQvF2=	NYfEfG5yW0GQR1XS
HCE-4	M4L0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnJdGcyUUN3ME2wMlAzOTR3IN88US=>	M1;yO3NCVkeHUh?=
DU-4475	NV\keJppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\yTWM2OD1yLkCyNVUh\|ryP	MmDMV2FPT0WU
A375	MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwMEKxO\|Eh\|ryP	MmPGV2FPT0WU
GB-1	NV2wZnJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jGeGlEPTB;MD6wNlE5QCEQvF2=	MmrMV2FPT0WU
CHP-212	NEjId3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDnTWM2OD1yLkCyNlEzKM7:TR?=	MX7TRW5ITVJ?
HT-1080	NX33Snd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fwPGlEPTB;MD6wNlIyPCEQvF2=	M4mzN3NCVkeHUh?=
M059J	M3my[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPQTWM2OD1yLkCyNlQyKM7:TR?=	MnfRV2FPT0WU
NMC-G1	M4TnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\kTWM2OD1yLkCyNlgh\|ryP	MYHTRW5ITVJ?
MRK-nu-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XJ[2lEPTB;MD6wNlMh\|ryP	M136[3NCVkeHUh?=
MFE-296	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHqVJdPUUN3ME2wMlAzOzJ{IN88US=>	NELOTpNUSU6JRWK=
LOXIMVI	M4rwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUD5TpV2UUN3ME2wMlAzOzJ\|IN88US=>	NFez[odUSU6JRWK=
CGTH-W-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljGTWM2OD1yLkCyN\|I5KM7:TR?=	Mmf2V2FPT0WU
CCRF-CEM	NGPHZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzzTWM2OD1yLkCyN\|I6KM7:TR?=	NIXwcGRUSU6JRWK=
ACHN	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnoXolvUUN3ME2wMlAzOzR3IN88US=>	MlXaV2FPT0WU
NCI-H1355	Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml[5TWM2OD1yLkCyOFAyKM7:TR?=	M1G3UXNCVkeHUh?=
NCI-H1651	M2LSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nKZmlEPTB;MD6wNlQ{OSEQvF2=	NITl[XNUSU6JRWK=
KINGS-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLhTWM2OD1yLkCyOFM{KM7:TR?=	M{HKW3NCVkeHUh?=
LS-123	Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\5cVVVUUN3ME2wMlAzPDN3IN88US=>	MXHTRW5ITVJ?
SNB75	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PZcmlEPTB;MD6wNlQ3PiEQvF2=	NUCzN2Q5W0GQR1XS
C3A	M3fUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{[wPGlEPTB;MD6wNlQ4PSEQvF2=	MnP1V2FPT0WU
HO-1-N-1	MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;XTWM2OD1yLkCyOVQ6KM7:TR?=	NWLrVmxPW0GQR1XS
EHEB	MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfxPZN1UUN3ME2wMlAzPTV3IN88US=>	M4jWe3NCVkeHUh?=
CAL-62	NUT3RYNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjXcFFPUUN3ME2wMlAzPTdizszN	NXnJ[HQyW0GQR1XS
U-118-MG	NVrScJE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXW0NoRLUUN3ME2wMlAzPTd4IN88US=>	Ml3lV2FPT0WU
HN	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlmxTWM2OD1yLkCyOVk{KM7:TR?=	MofJV2FPT0WU
HTC-C3	Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXoSmtGUUN3ME2wMlAzPjB5IN88US=>	M37HXnNCVkeHUh?=
KYSE-520	Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHiTWM2OD1yLkCyOlE{KM7:TR?=	NFvzfHRUSU6JRWK=
MZ1-PC	M3\CRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfsbWF{UUN3ME2wMlAzPjN7IN88US=>	NXfL[YFXW0GQR1XS
BCPAP	NFvn[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMEK2OFYh\|ryP	M121[nNCVkeHUh?=
RD	M3HYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrPV5RoUUN3ME2wMlAzPjV6IN88US=>	NVXGRpoyW0GQR1XS
NCI-H520	NGKyPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWD6dHUxUUN3ME2wMlAzPjZ2IN88US=>	NHXKbVhUSU6JRWK=
LXF-289	NWDGfHpnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnf1TWM2OD1yLkCyOlY5KM7:TR?=	MmLYV2FPT0WU
G-361	M4fZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3G2SGlEPTB;MD6wNlY4PyEQvF2=	NVLYPXZLW0GQR1XS
LB996-RCC	NWHKZ5N6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnOXXBxUUN3ME2wMlAzPzFizszN	NXXXVZd2W0GQR1XS
COR-L23	Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDqTYVrUUN3ME2wMlAzPzF\|IN88US=>	NX2yOG12W0GQR1XS
GP5d	NVLEXXh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjkXVRKSzVyPUCuNFI4OjNizszN	NYrud\|F6W0GQR1XS
SW1990	MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jI[mlEPTB;MD6wNlczPCEQvF2=	NGPP[nVUSU6JRWK=
PA-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHGTWM2OD1yLkCyO\|U2KM7:TR?=	M{PxR3NCVkeHUh?=
NCI-H2009	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDyTWM2OD1yLkCyO\|Yh\|ryP	NFH2XYpUSU6JRWK=
SR	MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rUN2lEPTB;MD6wNlc5PSEQvF2=	Mnu1V2FPT0WU
Ca9-22	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrrTWM2OD1yLkCyO\|k3KM7:TR?=	NVK3[3JFW0GQR1XS
SCC-15	M2nKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7Ddo5SUUN3ME2wMlAzQDBzIN88US=>	MkDNV2FPT0WU
ETK-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rZ[2lEPTB;MD6wNlgxPiEQvF2=	MXnTRW5ITVJ?
SCC-4	NE\tV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTBwMEK4NFkh\|ryP	MlnDV2FPT0WU
5637	MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\RepZKSzVyPUCuNFI5OjJizszN	MkPBV2FPT0WU
EW-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHUTWM2OD1yLkCyPFIzKM7:TR?=	NFO1fnNUSU6JRWK=
SW962	M1:5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\wTmVQUUN3ME2wMlAzQDV{IN88US=>	M4[yO3NCVkeHUh?=
HCE-T	M2PUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnz2TWM2OD1yLkCyPFYh\|ryP	NEjOcoRUSU6JRWK=
NCI-H2405	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTBwMEK4PFch\|ryP	NVzIcphsW0GQR1XS
A2058	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkX4TWM2OD1yLkCyPVI6KM7:TR?=	NEjLXINUSU6JRWK=
HCC2998	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwMEK5OFUh\|ryP	NED3e2JUSU6JRWK=
ONS-76	M1ixUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYmxRXZLUUN3ME2wMlAzQTV2IN88US=>	NWPjVFVNW0GQR1XS
DBTRG-05MG	MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwMEK5OVUh\|ryP	M2Lt[3NCVkeHUh?=
HuCCT1	NUnKfZZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwMEK5OlEh\|ryP	MUHTRW5ITVJ?
J82	Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LPNWlEPTB;MD6wN\|AxPyEQvF2=	MVTTRW5ITVJ?
MKN28	NGfYVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmiwTWM2OD1yLkCzNFEzKM7:TR?=	NXS1R\|V5W0GQR1XS
SW837	M12zeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXFTWM2OD1yLkCzNFE1KM7:TR?=	NIjjXVlUSU6JRWK=
no-10	M4i2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fBR2lEPTB;MD6wN\|AyPiEQvF2=	MVfTRW5ITVJ?
BC-3	NXSyN5hET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPaemlKSzVyPUCuNFMxOThizszN	NHXtboFUSU6JRWK=
no-11	NH31[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMEOwOFgh\|ryP	MWrTRW5ITVJ?
8305C	NVXFPYE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HPU2lEPTB;MD6wN\|A4OiEQvF2=	M{TFOXNCVkeHUh?=
COLO-679	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLzTWM2OD1yLkCzNVA4KM7:TR?=	MWfTRW5ITVJ?
CESS	MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwMEOxNkDPxE1?	NV;sc2ZpW0GQR1XS
BFTC-909	NXPsTWg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7sWWVKSzVyPUCuNFMyOjVizszN	MXXTRW5ITVJ?
MZ2-MEL	NY\JVHpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYm5VGhIUUN3ME2wMlA{OTd5IN88US=>	MU\TRW5ITVJ?
SW872	NXPCRmgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkT6TWM2OD1yLkCzNlE4KM7:TR?=	NED3fVdUSU6JRWK=
LB831-BLC	Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmX3TWM2OD1yLkCzNlE6KM7:TR?=	M2PTdHNCVkeHUh?=
SK-UT-1	NVTrW5dLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTBwMEOyNlEh\|ryP	MnrjV2FPT0WU
NCI-H1734	M1H6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHhZ49UUUN3ME2wMlA{OjNizszN	M1:zenNCVkeHUh?=
OVCAR-8	NGK3V3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTBwMEOyPFEh\|ryP	M{LtWXNCVkeHUh?=
NCI-H2087	M3:zcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHBTWM2OD1yLkCzNlg6KM7:TR?=	M3vCfXNCVkeHUh?=
U-87-MG	NWe2XJloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHizN3VKSzVyPUCuNFMzQSEQvF2=	NI\3S4xUSU6JRWK=
BC-1	M{XXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjU[oNKSzVyPUCuNFM{PjdizszN	M2X3PXNCVkeHUh?=
ES7	MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2S3bmlEPTB;MD6wN\|M4PCEQvF2=	MmLCV2FPT0WU
Daudi	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjPflBKSzVyPUCuNFM{PzZizszN	MVLTRW5ITVJ?
RS4-11	NHXUTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mni3TWM2OD1yLkCzN\|g{KM7:TR?=	M1;NdHNCVkeHUh?=
JiyoyeP-2003	Mo\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXS1NlBxUUN3ME2wMlA{Ozh6IN88US=>	M2CxR3NCVkeHUh?=
BL-70	NHnu[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\BWFJKSzVyPUCuNFM{QDlizszN	M{XuXnNCVkeHUh?=
OS-RC-2	MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwMEOzPVYh\|ryP	MoO1V2FPT0WU
SF268	MkPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDxTWM2OD1yLkCzOFAyKM7:TR?=	NFLGN25USU6JRWK=
BV-173	M1L5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TmO2lEPTB;MD6wN\|QzPiEQvF2=	MlXwV2FPT0WU
DMS-273	M4DHbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4q2SWlEPTB;MD6wN\|Q4QSEQvF2=	MVzTRW5ITVJ?
22RV1	NF:2OmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGWwdG5KSzVyPUCuNFM2ODdizszN	M1vpO3NCVkeHUh?=
ES8	M3jzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTBwMEO1N\|gh\|ryP	MXHTRW5ITVJ?
KYSE-150	MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwMEO2NFgh\|ryP	MVzTRW5ITVJ?
HCC1569	MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlS0TWM2OD1yLkCzOlA5KM7:TR?=	MnLiV2FPT0WU
NB5	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HkV2lEPTB;MD6wN\|YyOyEQvF2=	MWPTRW5ITVJ?
G-402	NUHLeo1YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2m1WGlEPTB;MD6wN\|YyPCEQvF2=	NUXo[XpuW0GQR1XS
NCI-H1693	MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLjN4tKSzVyPUCuNFM3OTdizszN	MmPoV2FPT0WU
LB2241-RCC	MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwMEO2OFIh\|ryP	NHfodpZUSU6JRWK=
KP-4	M{i5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVyz[4JHUUN3ME2wMlA{PjZ\|IN88US=>	M2P3cXNCVkeHUh?=
ML-2	MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fiR2lEPTB;MD6wN\|Y4OSEQvF2=	MXfTRW5ITVJ?
KU812	NUCzbodIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXtR4M4UUN3ME2wMlA{Pjh2IN88US=>	MYfTRW5ITVJ?
LS-411N	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIexXoNKSzVyPUCuNFM4OzFizszN	M3\RenNCVkeHUh?=
OAW-42	NHLwVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvOUIJOUUN3ME2wMlA{PzR5IN88US=>	NIi2e2xUSU6JRWK=
HCC38	NW\xT4xTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDTfJdKSzVyPUCuNFM4PzFizszN	MljSV2FPT0WU
Ca-Ski	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HEd2lEPTB;MD6wN\|c5PCEQvF2=	M3jienNCVkeHUh?=
Calu-3	NIrXfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTBwMEO3PFkh\|ryP	NEjjR4lUSU6JRWK=
KYSE-70	NHz0NYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHkTWM2OD1yLkCzPFEzKM7:TR?=	NUS0c2hTW0GQR1XS
D-392MG	NX:3RnBCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwMEO4OFIh\|ryP	NGn6TVFUSU6JRWK=
OVCAR-4	MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvDVHhKSzVyPUCuNFM5PThizszN	NEnScY5USU6JRWK=
Detroit562	NGfuU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkKzTWM2OD1yLkCzPFczKM7:TR?=	MVPTRW5ITVJ?
HEL	MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrmTWM2OD1yLkCzPFkyKM7:TR?=	NEfKbJVUSU6JRWK=
MONO-MAC-6	NWfR[ZdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\MTWM2OD1yLkCzPFk{KM7:TR?=	NXvGPFZ7W0GQR1XS
LoVo	NVqxWJRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13QPWlEPTB;MD6wN\|k{OyEQvF2=	NYnVNIF1W0GQR1XS
U-2-OS	MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMEO5N\|Uh\|ryP	NHTVW2tUSU6JRWK=
A172	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvlS49KSzVyPUCuNFM6PSEQvF2=	NFvmRmJUSU6JRWK=
OCUB-M	MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkGyTWM2OD1yLkCzPVYyKM7:TR?=	NWDI[4VIW0GQR1XS
SW48	NG\ve\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGG2SYpKSzVyPUCuNFQxOzFizszN	NUDOVI9PW0GQR1XS
HC-1	M{nPOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIP4[5BKSzVyPUCuNFQxPjlizszN	NEfmUXVUSU6JRWK=
KOSC-2	M4C3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTu[WtVUUN3ME2wMlA1OTFizszN	NYDn[ZNFW0GQR1XS
HDLM-2	Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTBwMESxNVQh\|ryP	MVnTRW5ITVJ?
CTV-1	NH3WSXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HYemlEPTB;MD6wOFEyPiEQvF2=	M1n0WnNCVkeHUh?=
SH-4	NXTRb4pnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHYTWM2OD1yLkC0NVQyKM7:TR?=	NYDQfVVnW0GQR1XS
SW756	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrkcVNKSzVyPUCuNFQyPTdizszN	NW\wTJlLW0GQR1XS
GCT	M3f4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwMESxOlEh\|ryP	M2T0TnNCVkeHUh?=
CHL-1	M4HWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEizVmVKSzVyPUCuNFQyPjlizszN	NYPiOGVnW0GQR1XS
LAMA-84	MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojlTWM2OD1yLkC0NVcyKM7:TR?=	M2LaWHNCVkeHUh?=
LS-1034	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHm[\|FKSzVyPUCuNFQyQTFizszN	NFPleGhUSU6JRWK=
NCI-H358	MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwMESyNVIh\|ryP	MV;TRW5ITVJ?
NB13	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHDWnFEUUN3ME2wMlA1OjJ5IN88US=>	NXfWNZd[W0GQR1XS
TE-9	NGqzcmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LJeWlEPTB;MD6wOFI{PyEQvF2=	MlLzV2FPT0WU
OE33	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXL6OXJvUUN3ME2wMlA1OjRzIN88US=>	MWPTRW5ITVJ?
CAL-120	MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzZTWM2OD1yLkC0NlQyKM7:TR?=	M3e4UHNCVkeHUh?=
DJM-1	M{nHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1u4NGlEPTB;MD6wOFI4OiEQvF2=	MXPTRW5ITVJ?
SK-MEL-24	MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHK3RVhKSzVyPUCuNFQzQDNizszN	MUPTRW5ITVJ?
VA-ES-BJ	NXrZ[FBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwMESyPVIh\|ryP	MXrTRW5ITVJ?
MMAC-SF	NUWySmtGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDWTWM2OD1yLkC0Nlk4KM7:TR?=	NV7j[os6W0GQR1XS
MZ7-mel	MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwMESzN{DPxE1?	NULE[3JSW0GQR1XS
BxPC-3	MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2D5TWlEPTB;MD6wOFM1OSEQvF2=	MoD0V2FPT0WU
HT-29	Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\ZVGlEPTB;MD6wOFM2PyEQvF2=	NIr6ZVNUSU6JRWK=
SK-MEL-30	MonIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzlTWM2OD1yLkC0N\|YzKM7:TR?=	MVjTRW5ITVJ?
CAL-33	M1rWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTRTWM2OD1yLkC0N\|c2KM7:TR?=	M2XlU3NCVkeHUh?=
COLO-680N	M133Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTBwMES0NFch\|ryP	NI\mXYVUSU6JRWK=
NH-12	NGDmcohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFmy[JVKSzVyPUCuNFQ1PCEQvF2=	NWf6W3JoW0GQR1XS
HCC1937	NGjxfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHieGNKSzVyPUCuNFQ1PTZizszN	MnL1V2FPT0WU
IMR-5	MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTxTIJKSzVyPUCuNFQ1QSEQvF2=	M{\qUHNCVkeHUh?=
MC-CAR	NEfqWVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zo[WlEPTB;MD6wOFU3QSEQvF2=	MlnxV2FPT0WU
NCI-H747	NWHBWHVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3XTWM2OD1yLkC0OVch\|ryP	NX;se4w4W0GQR1XS
NCI-H1792	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml63TWM2OD1yLkC0OVgyKM7:TR?=	NYDWTWpXW0GQR1XS
SW13	NG\LbnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1[zO2lEPTB;MD6wOFU6KM7:TR?=	M1TRbXNCVkeHUh?=
MLMA	M2HtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMES2NFkh\|ryP	M2\G[nNCVkeHUh?=
U251	M3;nPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTBwMES3OlMh\|ryP	NF3WcJlUSU6JRWK=
U031	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DScWlEPTB;MD6wOFc4OSEQvF2=	NHPRbIxUSU6JRWK=
ME-180	M3XSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrqPJJKSzVyPUCuNFQ4QDJizszN	NWLxPYtKW0GQR1XS
SK-MEL-3	M{DxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwMES4NFIh\|ryP	M{jzdHNCVkeHUh?=
MOLT-4	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLq[4tKSzVyPUCuNFQ5ODNizszN	MYHTRW5ITVJ?
PF-382	NWHVSoo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3UTWM2OD1yLkC0PFI3KM7:TR?=	NEXVTXNUSU6JRWK=
NUGC-3	NFf5TolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\ENFFOUUN3ME2wMlA1QDJ5IN88US=>	MWPTRW5ITVJ?
NCI-H1417	NVewNlZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXmNYVqUUN3ME2wMlA1QDlizszN	MljIV2FPT0WU
COLO-205	M3zQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTjOmZbUUN3ME2wMlA1QTF7IN88US=>	MX3TRW5ITVJ?
TE-441-T	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPNTWM2OD1yLkC0PVMh\|ryP	MkjHV2FPT0WU
MKN1	M2S2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPFWFhKSzVyPUCuNFQ6OyEQvF2=	M2fqPXNCVkeHUh?=
UM-UC-3	Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlr3TWM2OD1yLkC0PVUh\|ryP	MnPiV2FPT0WU
SF126	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFj3[5ZKSzVyPUCuNFUxOSEQvF2=	NGXJWmxUSU6JRWK=
LB1047-RCC	M3HETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwMEWwN\|Eh\|ryP	NVTReVlLW0GQR1XS
A253	M3jX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnZOnByUUN3ME2wMlA2ODV{IN88US=>	NVToOZAxW0GQR1XS
NCI-H1963	M4DwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwMEWxO\|Yh\|ryP	MXvTRW5ITVJ?
VM-CUB-1	NYK5SoM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\HUoRvUUN3ME2wMlA2OzFzIN88US=>	NHv5dmVUSU6JRWK=
T-24	M3fYSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3Sc2JoUUN3ME2wMlA2Ozh2IN88US=>	MYrTRW5ITVJ?
K-562	M1flbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDCU5RNUUN3ME2wMlA2Ozh5IN88US=>	MUPTRW5ITVJ?
ARH-77	NXHpWZhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrJNXNKSzVyPUCuNFU{QTVizszN	NHjVVHlUSU6JRWK=
CA46	NFPOSHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\ZeGlEPTB;MD6wOVQ{KM7:TR?=	MU\TRW5ITVJ?
HCC70	NInlT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwMEW0OVIh\|ryP	MV3TRW5ITVJ?
ST486	MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHlUlFKSzVyPUCuNFU2OjVizszN	NYTwNIRtW0GQR1XS
COLO-741	NFP2XYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVOyRmltUUN3ME2wMlA2PTNzIN88US=>	MXPTRW5ITVJ?
SK-PN-DW	NV7xT2hjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPO[opSUUN3ME2wMlA2PTh6IN88US=>	MWDTRW5ITVJ?
BL-41	MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTBwMEW1PVYh\|ryP	M{LRbXNCVkeHUh?=
D-263MG	NWq3[lJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzxe3hXUUN3ME2wMlA2Pjh\|IN88US=>	NWLVfIJsW0GQR1XS
KE-37	NGTUdphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHWxS2JKSzVyPUCuNFU3QDNizszN	MlPLV2FPT0WU
LU-134-A	NUPlZZE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrOTWM2OD1yLkC1O\|E2KM7:TR?=	MluxV2FPT0WU
HCC2157	Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPIRWhKSzVyPUCuNFU4OzNizszN	NUfpbmVWW0GQR1XS
GAK	MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTrTWM2OD1yLkC1O\|M1KM7:TR?=	MlTFV2FPT0WU
IST-SL2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7kSFhKSzVyPUCuNFU4PDNizszN	NVO4NlJVW0GQR1XS
KMOE-2	NUfNOXJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorFTWM2OD1yLkC1O\|Q6KM7:TR?=	NVnEeG1CW0GQR1XS
SW1573	NEL0PWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvHZ45KSzVyPUCuNFU5ODJizszN	MlrQV2FPT0WU
SCC-9	NETINmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLzcVVbUUN3ME2wMlA2QDdizszN	NXjLNXczW0GQR1XS
MDA-MB-361	M2nEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTBwMEW4O\|Ih\|ryP	MnexV2FPT0WU
BHT-101	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDESpdKSzVyPUCuNFU5PzZizszN	NVSyTmRMW0GQR1XS
NCI-H1770	NYLjRVBOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwMEW4O\|kh\|ryP	MU\TRW5ITVJ?
UACC-893	NUHzZ4RNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzmWpBKSzVyPUCuNFU5QTZizszN	M4HabXNCVkeHUh?=
NCI-H226	Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwMEW5PFgh\|ryP	MVjTRW5ITVJ?
HLE	M3u4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwME[wPFIh\|ryP	MYDTRW5ITVJ?
NCI-H1703	NH7nSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HueWlEPTB;MD6wOlE4QCEQvF2=	Mn3rV2FPT0WU
KURAMOCHI	MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1K4[2lEPTB;MD6wOlE5QSEQvF2=	NX73enBIW0GQR1XS
RH-1	NIG1W3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmK3TWM2OD1yLkC2NlMh\|ryP	MVzTRW5ITVJ?
DSH1	MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwME[yO{DPxE1?	MYHTRW5ITVJ?
CAMA-1	NID2ZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4e5PWlEPTB;MD6wOlMxOyEQvF2=	MlHrV2FPT0WU
NCI-H1437	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYT6[WQ5UUN3ME2wMlA3OzJ6IN88US=>	M4TiRnNCVkeHUh?=
HuP-T4	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nrPWlEPTB;MD6wOlU5PiEQvF2=	NUTadFdZW0GQR1XS
HCT-15	NXjKRmhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7QNmhKSzVyPUCuNFY2QTdizszN	NGnKdFJUSU6JRWK=
NCCIT	NXu1fnhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;wXGlEPTB;MD6wOlYxPCEQvF2=	NHT5bYdUSU6JRWK=
BOKU	MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXTXmNKSzVyPUCuNFY3PzRizszN	M3[xS3NCVkeHUh?=
FADU	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHSydYlKSzVyPUCuNFY4PDVizszN	M3PxbXNCVkeHUh?=
SUP-T1	M4q1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzQTWM2OD1yLkC2O\|Yh\|ryP	M4OwTXNCVkeHUh?=
L-363	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwME[5NFEh\|ryP	NGjsO\|JUSU6JRWK=
KNS-81-FD	M17t[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjwTWM2OD1yLkC2PVE5KM7:TR?=	MYnTRW5ITVJ?
SU-DHL-1	NYfMTXNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUH5ZY4yUUN3ME2wMlA3QTJizszN	M3jwWnNCVkeHUh?=
HuH-7	MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwMEewN\|Uh\|ryP	M{DsdHNCVkeHUh?=
BT-474	M4LnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTiTWM2OD1yLkC3NFYyKM7:TR?=	NUD1cVI4W0GQR1XS
CAPAN-1	NXy0elk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkL5TWM2OD1yLkC3NVQ{KM7:TR?=	MlO2V2FPT0WU
HEC-1	NHvNVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTBwMEexOlEh\|ryP	NGC2UllUSU6JRWK=
NOMO-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfaSHVKSzVyPUCuNFcyPzJizszN	NIfDXZBUSU6JRWK=
KM-H2	M1fPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\DT2lEPTB;MD6wO\|I1OSEQvF2=	MWnTRW5ITVJ?
EB2	NEnCd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTBwMEeyPFUh\|ryP	MmfEV2FPT0WU
LU-99A	Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMEeyPFch\|ryP	NXK4Z2lJW0GQR1XS
WSU-NHL	M4T3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2r1SmlEPTB;MD6wO\|MzQSEQvF2=	NYjxeZhjW0GQR1XS
Calu-1	MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmK3TWM2OD1yLkC3N\|MzKM7:TR?=	MXXTRW5ITVJ?
U-698-M	NUXBdYFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwMEezPFIh\|ryP	NWe0[I1EW0GQR1XS
T98G	NInJVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXPZYhNUUN3ME2wMlA4PDJzIN88US=>	MkTUV2FPT0WU
GI-ME-N	MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fiW2lEPTB;MD6wO\|QzPiEQvF2=	NGrFb4NUSU6JRWK=
LS-513	MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETWW3hKSzVyPUCuNFc1PTZizszN	M4jkOHNCVkeHUh?=
UACC-257	NIr0Z\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\ib2lEPTB;MD6wO\|UxPSEQvF2=	MXvTRW5ITVJ?
DK-MG	NWKyTnI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjPTWM2OD1yLkC3OVI3KM7:TR?=	NXHMfmJzW0GQR1XS
EW-11	NFTYb4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwMEe1N\|Uh\|ryP	MUHTRW5ITVJ?
CHP-126	M3S0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLKTWM2OD1yLkC3OVY2KM7:TR?=	NFv5RXhUSU6JRWK=
Saos-2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nGdGlEPTB;MD6wO\|U6PyEQvF2=	Mlf6V2FPT0WU
Ramos-2G6-4C10	NHS0R3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnCelNMUUN3ME2wMlA4PjR6IN88US=>	NWjwSJlyW0GQR1XS
L-428	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnGVppKSzVyPUCuNFc4ODRizszN	M2fSfnNCVkeHUh?=
HOP-92	NIjVS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;lNWlEPTB;MD6wO\|cyOSEQvF2=	NY\ZXYx5W0GQR1XS
PANC-08-13	NX;ibHdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfxXoRqUUN3ME2wMlA4PzF4IN88US=>	MkDEV2FPT0WU
TUR	Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzyfmxyUUN3ME2wMlA4PzN\|IN88US=>	NEfDUHZUSU6JRWK=
DMS-153	M{LTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPDXo5HUUN3ME2wMlA4PzN3IN88US=>	NIDyO2pUSU6JRWK=
NCI-N87	M2jJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwMEe3PVkh\|ryP	M2rwSHNCVkeHUh?=
ESS-1	MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTBwMEe4Olgh\|ryP	MmTCV2FPT0WU
CP66-MEL	NV\DdnlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjQbm5kUUN3ME2wMlA4QDh5IN88US=>	M4LXe3NCVkeHUh?=
NCI-SNU-1	NHfPOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTBwMEe4PFgh\|ryP	NE\xZoNUSU6JRWK=
Calu-6	MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTBwMEe5OlUh\|ryP	MmnSV2FPT0WU
COLO-668	NWK4SYxsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXlcpJKSzVyPUCuNFc6QDRizszN	MUjTRW5ITVJ?
SK-CO-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFv5TJdKSzVyPUCuNFc6QTJizszN	MV7TRW5ITVJ?
NCI-H2347	M3PFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljMTWM2OD1yLkC4NFI5KM7:TR?=	M3fMXHNCVkeHUh?=
CAL-27	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoK5TWM2OD1yLkC4NVU3KM7:TR?=	NFzJXZRUSU6JRWK=
COLO-684	M4nUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPMTWM2OD1yLkC4NVU5KM7:TR?=	NFGwOHFUSU6JRWK=
LNCaP-Clone-FGC	NGfkTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3ntOmlEPTB;MD6wPFE3PSEQvF2=	M4\oUHNCVkeHUh?=
NCI-H1304	NHjJOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvQW\|dKSzVyPUCuNFgzPzFizszN	MXLTRW5ITVJ?
KP-N-YS	M3;oeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwMEizOFUh\|ryP	MkjJV2FPT0WU
CP50-MEL-B	NGfXWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzTfYJoUUN3ME2wMlA5OzZ6IN88US=>	MXrTRW5ITVJ?
LAN-6	MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDQbZd2UUN3ME2wMlA5PDl6IN88US=>	NIX5boRUSU6JRWK=
ABC-1	M3jRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XRdGlEPTB;MD6wPFc2QSEQvF2=	M{HzXHNCVkeHUh?=
ES3	M1zScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTBwMEi3OlMh\|ryP	MoT5V2FPT0WU
COLO-792	M4\kT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4P5XWlEPTB;MD6wPFg2PSEQvF2=	NYfSOpNYW0GQR1XS
J-RT3-T3-5	MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;JTWM2OD1yLkC4PVY5KM7:TR?=	NIXlZ3pUSU6JRWK=
EFO-21	NUnLOZJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofMTWM2OD1yLkC4PVkyKM7:TR?=	MYLTRW5ITVJ?
MDA-MB-231	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\KUlVKSzVyPUCuNFkxQDJizszN	M4X1Z3NCVkeHUh?=
SBC-5	Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWD0e2xEUUN3ME2wMlA6OTl\|IN88US=>	NIK2UZVUSU6JRWK=
SAS	M3e2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMEmyNVUh\|ryP	M1H5S3NCVkeHUh?=
SNU-387	NWiwOGt7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TzSGlEPTB;MD6wPVIyQCEQvF2=	MVTTRW5ITVJ?
EVSA-T	MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3NSI9KSzVyPUCuNFkzPjVizszN	M1TpN3NCVkeHUh?=
MHH-PREB-1	NGj5emhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrsTWM2OD1yLkC5N\|Eh\|ryP	NI[wNlFUSU6JRWK=
KARPAS-45	NFPkemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrTS4ZDUUN3ME2wMlA6OzR3IN88US=>	NIHaXHpUSU6JRWK=
SJRH30	NWrHZ4JmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\MTWM2OD1yLkC5OFQ1KM7:TR?=	MXXTRW5ITVJ?
JEG-3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jtUmlEPTB;MD6wPVUxPSEQvF2=	M1Lw[3NCVkeHUh?=
NB12	M{PZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTBwMEm1NVgh\|ryP	M1fD[nNCVkeHUh?=
HCC1419	NWLkWo9ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwMEm1OFEh\|ryP	M4TXRnNCVkeHUh?=
HCC1599	NUn1bXF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fQVmlEPTB;MD6wPVYxOSEQvF2=	M2LsSXNCVkeHUh?=
IPC-298	NV;0OlNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrISYxNUUN3ME2wMlA6PjR2IN88US=>	NWW5bZRlW0GQR1XS
MPP-89	NIf0NmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjUSHM{UUN3ME2wMlA6PzJzIN88US=>	MWjTRW5ITVJ?
HT-1376	NV\PUlBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUX5XZgzUUN3ME2wMlA6QDZzIN88US=>	MV\TRW5ITVJ?
MDA-MB-468	MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmraTWM2OD1yLkC5PVg2KM7:TR?=	MnTLV2FPT0WU
HCC2218	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHxRlFKUUN3ME2wMlA6QTl7IN88US=>	M17HbnNCVkeHUh?=
LK-2	M13KcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13FSmlEPTB;MD6xNFE4PiEQvF2=	MVLTRW5ITVJ?
GR-ST	NWHjPYhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{O4XmlEPTB;MD6xNFIyKM7:TR?=	NHjLWnBUSU6JRWK=
PFSK-1	MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vJVmlEPTB;MD6xNFI3PyEQvF2=	NGOxd5FUSU6JRWK=
NCI-H2052	MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HuO2lEPTB;MD6xNFQxPyEQvF2=	MojtV2FPT0WU
A673	NEjj[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIWy[4VKSzVyPUCuNVA1OzFizszN	Mmf3V2FPT0WU
EKVX	NUPFcFBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2mzcGlEPTB;MD6xNFQ5OyEQvF2=	NWPEUpZ5W0GQR1XS
23132-87	NGDaTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIryU5RKSzVyPUCuNVA1QDhizszN	M1HhZ3NCVkeHUh?=
EW-18	M1Htb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{S0[GlEPTB;MD6xNFYxPCEQvF2=	M3nHVHNCVkeHUh?=
KU-19-19	NU\jdo5YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mme5TWM2OD1yLkGwPFE4KM7:TR?=	NWjObYdPW0GQR1XS
NCI-H441	NXHjU4x5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLQUGp7UUN3ME2wMlExQDl7IN88US=>	M{\pTXNCVkeHUh?=
COLO-824	M4TZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDNS\|JKSzVyPUCuNVExOiEQvF2=	NV64TXJ{W0GQR1XS
HCC1806	MnS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDITWM2OD1yLkGxNVA5KM7:TR?=	M2\qWnNCVkeHUh?=
SK-MM-2	MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwMUGxOFUh\|ryP	NVvDN3lnW0GQR1XS
DEL	M2fsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2n5Z2lEPTB;MD6xNVE6OiEQvF2=	MVnTRW5ITVJ?
NCI-H661	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDXTWM2OD1yLkGxNVk2KM7:TR?=	NIm3U5ZUSU6JRWK=
LC4-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTBwMUG0OlYh\|ryP	NECyXZJUSU6JRWK=
BEN	Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwMUG2NFch\|ryP	NGPhR45USU6JRWK=
RPMI-8226	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYSz[lA3UUN3ME2wMlEyPzF7IN88US=>	NULZdGFSW0GQR1XS
AU565	MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIX5copKSzVyPUCuNVE5OzFizszN	MnexV2FPT0WU
CAS-1	MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLNbJBKSzVyPUCuNVE6PjRizszN	MmHDV2FPT0WU
UACC-62	NIiwSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlX6TWM2OD1yLkGyNVIh\|ryP	MVLTRW5ITVJ?
C-4-II	NWrIblRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwMUKxO{DPxE1?	MnnoV2FPT0WU
DMS-53	M2fLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGC5fohKSzVyPUCuNVIzPzZizszN	NYXVRXFMW0GQR1XS
SK-MEL-2	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMUK0OkDPxE1?	Ml\mV2FPT0WU
S-117	NHfPdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfJTWM2OD1yLkGyOlc1KM7:TR?=	NUTGRWFLW0GQR1XS
ChaGo-K-1	NEPibIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvITWM2OD1yLkGyOlk6KM7:TR?=	MYXTRW5ITVJ?
KMS-12-PE	M4rvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGr1eZNKSzVyPUCuNVI5PjlizszN	NFfoT4JUSU6JRWK=
PC-3	NWPKdmcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwMUOxO\|ch\|ryP	Mk\mV2FPT0WU
RERF-LC-MS	MmXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLUTWM2OD1yLkGzOFMh\|ryP	MmDJV2FPT0WU
GMS-10	MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMUO0OFQh\|ryP	M1X2cXNCVkeHUh?=
CTB-1	M3vTV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjwTWM2OD1yLkGzOFY6KM7:TR?=	M1Pl[XNCVkeHUh?=
SCC-25	NXrxVnlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTBwMUO1PFgh\|ryP	NUW1WotZW0GQR1XS
NCI-H1755	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXCV5pKSzVyPUCuNVM5OjdizszN	NUW1cWNZW0GQR1XS
D-542MG	Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwMUO5OlUh\|ryP	NWfPbWoyW0GQR1XS
KARPAS-422	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nOZWlEPTB;MD6xOFA{PyEQvF2=	NXTad2pCW0GQR1XS
OVCAR-3	M3;GUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlThTWM2OD1yLkG0NFc5KM7:TR?=	NXPsRZkyW0GQR1XS
NCI-H1092	NEf0[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XOXmlEPTB;MD6xOFExOSEQvF2=	Mm\GV2FPT0WU
HH	M2rwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwMUSyNFEh\|ryP	NYfoc5BFW0GQR1XS
NB1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHQV5hTUUN3ME2wMlE1PDJ4IN88US=>	M4fudXNCVkeHUh?=
HD-MY-Z	M2GwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3ZflhuUUN3ME2wMlE1PDJ7IN88US=>	Ml\TV2FPT0WU
SHP-77	NHzaT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1T6XGlEPTB;MD6xOFQ4OiEQvF2=	Mlv0V2FPT0WU
U-266	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vxcGlEPTB;MD6xOFQ5KM7:TR?=	MVLTRW5ITVJ?
GI-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTBwMUS3O\|Ih\|ryP	MV7TRW5ITVJ?
NCI-H1522	M3XCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTBwMUS3PFch\|ryP	MWjTRW5ITVJ?
647-V	NHv3VWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDpRXRsUUN3ME2wMlE1QTR{IN88US=>	MlO5V2FPT0WU
HCT-116	NGHlRZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYf4S2hCUUN3ME2wMlE2OTZ7IN88US=>	NWf5V45tW0GQR1XS
NCI-H2081	NInYW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnYW5pKSzVyPUCuNVUzOThizszN	MWHTRW5ITVJ?
THP-1	M3;oUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzVTWM2OD1yLkG1N\|M{KM7:TR?=	MYfTRW5ITVJ?
LU-165	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTWWnpKSzVyPUCuNVU1OTNizszN	NWWwS5F7W0GQR1XS
RCM-1	M4HJNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMUW2PEDPxE1?	MX3TRW5ITVJ?
COR-L279	Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXwRY9PUUN3ME2wMlE2QDN4IN88US=>	M2rkWHNCVkeHUh?=
SK-NEP-1	NFG3Z\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTBwMUW4PVkh\|ryP	MmPXV2FPT0WU
KLE	NULleJR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1[xUmlEPTB;MD6xOlE3QSEQvF2=	M4LJSXNCVkeHUh?=
NCI-H2170	NUnheld6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwMU[zNFQh\|ryP	Ml\tV2FPT0WU
TGW	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMU[0O\|Eh\|ryP	NUKwSY9LW0GQR1XS
CAL-72	NW[5W4RlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMU[1PUDPxE1?	NFKxV2xUSU6JRWK=
K052	M1jW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfOU3BKSzVyPUCuNVcxPjFizszN	NHrkeY9USU6JRWK=
COR-L88	NETWdGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnldZJKSzVyPUCuNVcyOTRizszN	MWnTRW5ITVJ?
HSC-4	M2fCVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTBwMUexOkDPxE1?	MULTRW5ITVJ?
GOTO	NIXVcYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTBwMUeyOFYh\|ryP	NEPOW\|dUSU6JRWK=
MEG-01	NG\jVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPITYhzUUN3ME2wMlE4OjV5IN88US=>	MWrTRW5ITVJ?
MDA-MB-134-VI	Mly2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwMUezOlch\|ryP	MWfTRW5ITVJ?
NCI-H596	Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwMUezPEDPxE1?	MlKzV2FPT0WU
EW-3	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUP2NFV{UUN3ME2wMlE4PDh4IN88US=>	MmLsV2FPT0WU
NCI-H1573	M3rvfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLNOmhZUUN3ME2wMlE4Pjd6IN88US=>	M4ixUXNCVkeHUh?=
SKG-IIIa	NWCwN41mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jJbGlEPTB;MD6xO\|gxPyEQvF2=	MVXTRW5ITVJ?
SK-N-DZ	M{\yeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTBwMUe4PFMh\|ryP	NXe4Z21sW0GQR1XS
EGI-1	Mlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkX6TWM2OD1yLkG3PVch\|ryP	MkGwV2FPT0WU
COLO-320-HSR	MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHhTWM2OD1yLkG4OFk{KM7:TR?=	MljnV2FPT0WU
DOHH-2	M4XhOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\vNW5KSzVyPUCuNVg2PjlizszN	NHH2fXJUSU6JRWK=
MS-1	NFrldHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHWTWM2OD1yLkG4OkDPxE1?	NX32OZdlW0GQR1XS
NCI-H2171	MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPMVGZvUUN3ME2wMlE5PjR7IN88US=>	M4rDSHNCVkeHUh?=
NCI-H526	M4rHfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;RTWM2OD1yLkG4Olk3KM7:TR?=	MoK5V2FPT0WU
MDA-MB-415	NVTrfXNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjEZYRoUUN3ME2wMlE6PzR6IN88US=>	MmXEV2FPT0WU
ECC4	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHIfVNKSzVyPUCuNVk5PjNizszN	NVn0WnRSW0GQR1XS
C2BBe1	NFXsbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4G4XmlEPTB;MD6xPVg6OyEQvF2=	MWPTRW5ITVJ?
TE-11	M4CwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXYTWM2OD1yLkG5PVc2KM7:TR?=	MmfJV2FPT0WU
LU-65	MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTQd\|U5UUN3ME2wMlIxOjFzIN88US=>	M{Pvb3NCVkeHUh?=
MKN45	MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;NTWM2OD1yLkKwOlQh\|ryP	NVrz[IozW0GQR1XS
TGBC1TKB	NGixe\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfOUmlKSzVyPUCuNlA6QTdizszN	NV3KUYl[W0GQR1XS
NCI-H2196	NUXl[npCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljmTWM2OD1yLkKxO\|Q4KM7:TR?=	MXPTRW5ITVJ?
M14	NW\LTW91T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHS4PIlKSzVyPUCuNlE5ODNizszN	NE[xT4FUSU6JRWK=
NCI-H1436	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGCzcnVKSzVyPUCuNlE5OjZizszN	Mo\BV2FPT0WU
EB-3	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2Phc2lEPTB;MD6yNlM4PiEQvF2=	NEPtVplUSU6JRWK=
HT	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\FTWM2OD1yLkKyOVY3KM7:TR?=	M36zWXNCVkeHUh?=
A3-KAW	NF7DUoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHtTWM2OD1yLkKyO\|A5KM7:TR?=	NHjvPYxUSU6JRWK=
DB	NG\DZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwMkK4OlUh\|ryP	NWjJR4l6W0GQR1XS
KARPAS-299	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfIeVJKSzVyPUCuNlI6QTRizszN	NH\rTohUSU6JRWK=
IM-9	M2rVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwMkO0O\|Yh\|ryP	NYPuVHdFW0GQR1XS
NCI-H838	M1rXUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVqwOGFNUUN3ME2wMlI{PzF2IN88US=>	NGDrPFFUSU6JRWK=
NB10	NFXpTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjwO\|JKSzVyPUCuNlM4OzFizszN	MWXTRW5ITVJ?
NCI-H2141	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnqcllJUUN3ME2wMlI{QDRzIN88US=>	MkDGV2FPT0WU
LB647-SCLC	MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHvd3hZUUN3ME2wMlI1ODF2IN88US=>	NGWwe2FUSU6JRWK=
NCI-H23	MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwMkSwOVkh\|ryP	NWrkV5VEW0GQR1XS
MN-60	M4P1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2G3S2lEPTB;MD6yOFI{QSEQvF2=	MUnTRW5ITVJ?
CAL-148	NILvVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTBwMkSyPFIh\|ryP	NY[zc\|ZTW0GQR1XS
EFE-184	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjKPJo{UUN3ME2wMlI1PTl5IN88US=>	NI[2Z3ZUSU6JRWK=
TE-6	NYfmbZhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwMkS2NVIh\|ryP	M2XzOHNCVkeHUh?=
SN12C	Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jQWWlEPTB;MD6yOFY6PCEQvF2=	NXvG[GFqW0GQR1XS
CAKI-1	NXm2ZYZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHCPVZzUUN3ME2wMlI2ODh4IN88US=>	Mk\zV2FPT0WU
MHH-NB-11	NWixdGc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEX2c3NKSzVyPUCuNlU{PSEQvF2=	M4nWZ3NCVkeHUh?=
DOK	NGHkOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwMkW5N{DPxE1?	Mk\LV2FPT0WU
Raji	MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjFSlBKSzVyPUCuNlY3ODNizszN	M1n4b3NCVkeHUh?=
OAW-28	NWDaSFJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1u3dGlEPTB;MD6yOlY4PyEQvF2=	MWfTRW5ITVJ?
P30-OHK	M1nac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHKTWM2OD1yLkK2PVA2KM7:TR?=	M{fDSHNCVkeHUh?=
NCI-H69	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwMkeyNFEh\|ryP	M1:zVnNCVkeHUh?=
SK-N-AS	MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PB[WlEPTB;MD6yO\|IzKM7:TR?=	NH\kdolUSU6JRWK=
BE-13	NGLZ[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwMkeyOFkh\|ryP	NUnDWGQ5W0GQR1XS
NCI-H1618	M4C1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TvemlEPTB;MD6yO\|UyKM7:TR?=	MnrqV2FPT0WU
NCI-SNU-5	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnuTWM2OD1yLkK3OlE{KM7:TR?=	NGHaNpBUSU6JRWK=
NCI-H1694	NEHm[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXSOlM1UUN3ME2wMlI4PzN\|IN88US=>	Mo\IV2FPT0WU
RL	M3vE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwMkixO\|Qh\|ryP	MVfTRW5ITVJ?
SW684	NXzGeGsxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTBwMkizPFMh\|ryP	MmfnV2FPT0WU
EW-24	NEfPT5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwMki4NUDPxE1?	NGjzRY9USU6JRWK=
NCI-H510A	MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjaXo5XUUN3ME2wMlI6OzB2IN88US=>	M3PSOXNCVkeHUh?=
Mo-T	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGS0[2JKSzVyPUCuNlk{OzFizszN	M1P4ZnNCVkeHUh?=
LB373-MEL-D	NICweoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PGbWlEPTB;MD6yPVQ{OSEQvF2=	NHfaV5NUSU6JRWK=
NCI-H28	NH;PT2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fnbWlEPTB;MD6yPVg{PyEQvF2=	NUnC[IhYW0GQR1XS
NCI-H446	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnuxTWM2OD1yLkK5PVIyKM7:TR?=	NYnLOnVrW0GQR1XS
L-540	M3XHbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlS2TWM2OD1yLkOwNFg6KM7:TR?=	Ml;CV2FPT0WU
MKN7	NUXLXo01T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDYTZRKSzVyPUCuN\|A3OzlizszN	M33VT3NCVkeHUh?=
OPM-2	Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoD4TWM2OD1yLkOxNFY1KM7:TR?=	MULTRW5ITVJ?
BT-20	MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwM{GwPVkh\|ryP	MWDTRW5ITVJ?
KP-N-YN	NYTNd25mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXLbmxFUUN3ME2wMlMyOTF6IN88US=>	M3XE[HNCVkeHUh?=
MDA-MB-175-VII	NU\GU44xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PNVWlEPTB;MD6zNlM1QCEQvF2=	MlHzV2FPT0WU
EFM-19	Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDEPI9EUUN3ME2wMlM{OTN{IN88US=>	NWrOVm02W0GQR1XS
COLO-678	NGnE[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\5Uo1KSzVyPUCuN\|M{QDlizszN	NU\xO\|NZW0GQR1XS
COLO-829	M4XxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{mxV2lEPTB;MD6zOFQ2OiEQvF2=	NEnEb2tUSU6JRWK=
A704	M{LnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHm0enBKSzVyPUCuN\|Q6OjNizszN	NVPFd5lrW0GQR1XS
NCI-H719	M3jHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwM{WxNlQh\|ryP	NUf6[201W0GQR1XS
MFE-280	NHX4[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTBwM{W3NVUh\|ryP	M2L5e3NCVkeHUh?=
DMS-114	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWj1OJJQUUN3ME2wMlM3OTJizszN	MXXTRW5ITVJ?
RMG-I	M3\aZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4Dvd2lEPTB;MD6zOlY6OSEQvF2=	MUPTRW5ITVJ?
SK-N-FI	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwM{e2N\|ch\|ryP	MV3TRW5ITVJ?
LB2518-MEL	M33iXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTBwNEC4O\|Ih\|ryP	NWnmTZdoW0GQR1XS
IST-MES1	M3fZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHDfHNKSzVyPUCuOFEyKM7:TR?=	NUficXdFW0GQR1XS
HPAF-II	MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvWbnlKSzVyPUCuOFEyOTdizszN	MXfTRW5ITVJ?
NCI-H1882	MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfJTWM2OD1yLkSxO\|g1KM7:TR?=	NUXX[2hGW0GQR1XS
JVM-2	MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33ofWlEPTB;MD60OFQxOSEQvF2=	NXntSGN2W0GQR1XS
T47D	M4jVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPveohKSzVyPUCuOFQ2OjhizszN	M4XMNXNCVkeHUh?=
MHH-CALL-2	NVraTHJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{m3SWlEPTB;MD60OFg{KM7:TR?=	M2HZTHNCVkeHUh?=
NCI-H716	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7lTWM2OD1yLkS0PFQ5KM7:TR?=	M13TfHNCVkeHUh?=
NEC8	NH6zfVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPVTWM2OD1yLkS1NVQ2KM7:TR?=	MmfvV2FPT0WU
UACC-812	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUizN2M6UUN3ME2wMlQ3Pzd4IN88US=>	MYPTRW5ITVJ?
D-502MG	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jobmlEPTB;MD60PFA{KM7:TR?=	M4DOWnNCVkeHUh?=
CaR-1	NYL4ZohoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIj4cFFKSzVyPUCuOVA{PjdizszN	NEfLU3JUSU6JRWK=
LU-139	M1TtPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\iTWM2OD1yLkWxOFU4KM7:TR?=	M{XOVHNCVkeHUh?=
RPMI-8402	NEPXclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Wyc2lEPTB;MD61NlIxPyEQvF2=	MXLTRW5ITVJ?
SW1088	NHK3VVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorUTWM2OD1yLkWzPFY6KM7:TR?=	NIGxfXpUSU6JRWK=
JVM-3	NWi4UHR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\OZW9KSzVyPUCuOVQyOTdizszN	M4GxRXNCVkeHUh?=
YAPC	MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfGcYNSUUN3ME2wMlU2OjFzIN88US=>	NVHmTYpnW0GQR1XS
KG-1	MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwNUW5PFQh\|ryP	MYrTRW5ITVJ?
C32	NGTjcFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTHWnVKSzVyPUCuOVc{OTNizszN	NHL0R4hUSU6JRWK=
IST-SL1	NFPZcHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwNkC0N\|Uh\|ryP	NFrpXm9USU6JRWK=
NCI-H2126	MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\CbmxKSzVyPUCuOlMyPTJizszN	NVr1e2pIW0GQR1XS
HCC1954	MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XBdWlEPTB;MD62OFczPiEQvF2=	M1LMfXNCVkeHUh?=
WM-115	NHzoR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXoV3ZGUUN3ME2wMlY2ODl{IN88US=>	MmXhV2FPT0WU
NB6	MmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfOeFhKSzVyPUCuOlc{OzVizszN	NVK2dWQ2W0GQR1XS
TYK-nu	NGnVZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\RSohKSzVyPUCuOlc6PTJizszN	NFzYVYhUSU6JRWK=
KY821	M4\QWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLYd4pSUUN3ME2wMlcxOjJ7IN88US=>	MUfTRW5ITVJ?
SIMA	NV;pU5JiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXBbotKSzVyPUCuO\|E4OTlizszN	M2OySXNCVkeHUh?=
RCC10RGB	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17TZmlEPTB;MD63NVkyQCEQvF2=	NUfSfWJTW0GQR1XS
LN-405	M1n2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojmTWM2OD1yLke0N\|Yh\|ryP	NGLOe3lUSU6JRWK=
NCI-H1155	NXzPZlJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHveoRKSzVyPUCuO\|Q5PjhizszN	M2XlcnNCVkeHUh?=
SCLC-21H	MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrDT3I3UUN3ME2wMlc3QTB\|IN88US=>	NXrHbotmW0GQR1XS
DMS-79	M4rX[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjv[JhKSzVyPUCuO\|c5PDVizszN	NGjKXWRUSU6JRWK=
EC-GI-10	NFG2SJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwN{e5O\|Uh\|ryP	NYHG[5JUW0GQR1XS
KNS-42	NG\adIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fnSWlEPTB;MD63PFg{OSEQvF2=	NXq1flllW0GQR1XS
SNU-475	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLETWM2OD1yLke5NlAzKM7:TR?=	NEPJe3RUSU6JRWK=
SF539	NUHSV5hwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHwfoFtUUN3ME2wMlc6QTJ3IN88US=>	MWTTRW5ITVJ?
SW1417	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PrS2lEPTB;MD64NVM{QSEQvF2=	MV3TRW5ITVJ?
ATN-1	NYrBSXpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nOZmlEPTB;MD64OVEyPSEQvF2=	MonNV2FPT0WU
PLC-PRF-5	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVS4OZRbUUN3ME2wMlg5PDd3IN88US=>	MUPTRW5ITVJ?
HT-3	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwOEm0NkDPxE1?	M33MN3NCVkeHUh?=
MDA-MB-453	NGTycVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYm2SoZEUUN3ME2wMlkxOzB2IN88US=>	MUnTRW5ITVJ?
HAL-01	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUP2bGU2UUN3ME2wMlk6Ozd7IN88US=>	MoLHV2FPT0WU
NCI-H1993	NUCyW4JQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTFwMES2OVch\|ryP	Ml7sV2FPT0WU
NCI-H2227	NVviU3pyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTFwMES5PFEh\|ryP	NYDX[nZoW0GQR1XS
LP-1	MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTFwME[5N{DPxE1?	NYLTdWNKW0GQR1XS
P31-FUJ	Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTFwMUC3OlYh\|ryP	M2rNUXNCVkeHUh?=
NCI-H64	NX7DVHh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2n5bGlEPTB;MT6xOVQzKM7:TR?=	NWOwUGo4W0GQR1XS
SW1463	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEO1bW1KSzVyPUGuNVg{PDlizszN	M{nVeHNCVkeHUh?=
SK-MEL-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvsTWM2OD1zLkKwOVk2KM7:TR?=	M4G3T3NCVkeHUh?=
TALL-1	NH3pemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDxS2dKSzVyPUGuNlUyPjVizszN	MnLKV2FPT0WU
RO82-W-1	NWLCbnVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnG0TWM2OD1zLkOzN\|M6KM7:TR?=	MlPTV2FPT0WU
NCI-H1581	NHjVS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTZWmFpUUN3ME2xMlM2Pjh5IN88US=>	NX\EfVVyW0GQR1XS
NCI-H748	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTLTWM2OD1zLkO1O\|M5KM7:TR?=	MonXV2FPT0WU
HCC1187	Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfwbVY5UUN3ME2xMlU2PTJ{IN88US=>	M1\mV3NCVkeHUh?=
EoL-1-cell	M{flTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDSNXJKSzVyPUGuOVg5QDlizszN	NYH0TYRpW0GQR1XS
HuO-3N1	NWjCXY46T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4Lwd2lEPTB;MT64N\|QyOiEQvF2=	M3TK[3NCVkeHUh?=
NCI-H1793	NV;pTVlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDxSWhKSzVyPUGuPFc2QTNizszN	NXLxbIk3W0GQR1XS
Caov-3	M{LWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fDfmlEPTB;Mj6wNFYzPSEQvF2=	NFTlTllUSU6JRWK=
JAR	NWnjXnlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjDTFlKSzVyPUKuNFc6OiEQvF2=	M4H4WnNCVkeHUh?=
SK-MEL-28	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HEPWlEPTB;Mj6xPFA6QCEQvF2=	MnrGV2FPT0WU
EM-2	NH3INGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTJwMkCyPVMh\|ryP	MU\TRW5ITVJ?
Mewo	M1fCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jGXmlEPTB;Mj6yNlI3PSEQvF2=	M17xXnNCVkeHUh?=
NCI-H720	MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUn4d4N1UUN3ME2yMlI3PTh3IN88US=>	M4PiTXNCVkeHUh?=
CAL-54	MmL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;T[GY{UUN3ME2yMlI3Pzl3IN88US=>	MljIV2FPT0WU
MC116	M1zLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrCTWM2OD1{LkO2N\|k4KM7:TR?=	NHHKZ41USU6JRWK=
DG-75	M2LKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPmOFh2UUN3ME2yMlQ5PTd4IN88US=>	NF;aUIZUSU6JRWK=
HCC1143	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DjVGlEPTB;Mj61NFY2QCEQvF2=	NYXVT5FKW0GQR1XS
FTC-133	NHvwdpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTCTWM2OD1{LkWzOlg6KM7:TR?=	MnvKV2FPT0WU
AsPC-1	M1fINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTDdGUzUUN3ME2yMlU{QTJ7IN88US=>	MYTTRW5ITVJ?
NCI-H889	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XhWGlEPTB;Mj61OlcxPiEQvF2=	NEi3TJRUSU6JRWK=
HT55	M3;4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfmdnpKSzVyPUKuOlIxOTlizszN	MkLDV2FPT0WU
UMC-11	NIf4WlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\kWo5sUUN3ME2yMlc5PzF3IN88US=>	NEnGWmFUSU6JRWK=
P12-ICHIKAWA	MoHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXLWlJKSzVyPUKuPFIxPDZizszN	M4TxcHNCVkeHUh?=
HCC1395	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHr6NYNKSzVyPUKuPVg3ODJizszN	NXe1O5RHW0GQR1XS
D-283MED	M1XjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGCzRZhKSzVyPUOuNVg6OzdizszN	MnvQV2FPT0WU
COLO-800	NFnkcWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFu0OnZKSzVyPUOuN\|M5QTdizszN	MoLNV2FPT0WU
MFM-223	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MomyTWM2OD1\|LkO2NFk4KM7:TR?=	M{LDXHNCVkeHUh?=
TE-5	M1zxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;PdnVKSzVyPUSuOVYyPDdizszN	NYPkZ4J6W0GQR1XS
NCI-H209	MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rhU2lEPTB;ND63PFU4OiEQvF2=	M2TwfXNCVkeHUh?=
SiHa	MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzHd5RYUUN3ME20Mlk2OjB\|IN88US=>	M4XNN3NCVkeHUh?=
NCI-H1395	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonVTWM2OD13LkGwOlM{KM7:TR?=	NXrYWpFLW0GQR1XS
A498	NW\RbFJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HQ[GlEPTB;NT6yNVI2OSEQvF2=	NETMWWFUSU6JRWK=
ES5	M1[5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHO5eIxKSzVyPUWuOlEyPzhizszN	NXjy[mI1W0GQR1XS
MDA-MB-157	MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTVwNk[0OFMh\|ryP	NIXIS2hUSU6JRWK=
NCI-H1623	NVfJS2FjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUm0V2ZFUUN3ME21Mlg{PTV4IN88US=>	MU\TRW5ITVJ?
RPMI-8866	NVG1NolnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3IUWFKSzVyPUWuPFQ4QTJizszN	MkW2V2FPT0WU
LC-1F	NUP4WIhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTZwMEmyPVEh\|ryP	M2rzV3NCVkeHUh?=
TCCSUP	MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTZwNkCzOFkh\|ryP	NXP0T2V1W0GQR1XS
TT	NF7ze\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHWenlKSzVyPUiuN\|MxODlizszN	MlHqV2FPT0WU
NCI-H1838	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHm1SlFKSzVyPUiuOVE4OzFizszN	NFi1dWFUSU6JRWK=
NCI-H322M	M1\qO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\lTWM2OD17LkG2NlgyKM7:TR?=	NF7CRmZUSU6JRWK=
NCI-H187	M2O5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEftTm5KSzVyPUmuOVE5OzVizszN	MnfvV2FPT0WU
SBC-1	MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTlwOUO2OVYh\|ryP	NX3iUnFKW0GQR1XS
SCC-3	M{TxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\RTWM2OD1zMD61Olc6KM7:TR?=	NH;YSItUSU6JRWK=
SW948	NY\IPGhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nCSGlEPTB;MUCuO\|UyOSEQvF2=	MmjuV2FPT0WU
CPC-N	M3\GZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTFzLkCwO{DPxE1?	NIX4SpNUSU6JRWK=
TGBC24TKB	NGHmU41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTF\|LkWyPUDPxE1?	NW[1PG0zW0GQR1XS
NCI-H2452	M3njOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjWdW9KSzVyPUG0Mlc{KM7:TR?=	NWD0TYc3W0GQR1XS
Hs-578-T	NHe4VIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvY[oRKSzVyPUG4MlU4PTlizszN	M4TFeXNCVkeHUh?=
DV-90	M{Pz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTkTWM2OD1zOD65PVQ2KM7:TR?=	MnrSV2FPT0WU
NCI-H1563	Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWn4VJd[UUN3ME2xPU44QDh6IN88US=>	MmC4V2FPT0WU
SW780	NHf5T3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojhTWM2OD1{MT6xN\|E5KM7:TR?=	MYLTRW5ITVJ?
NCI-H345	NVrNcm5nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnizTWM2OD1{MT64O\|c6KM7:TR?=	Mn3JV2FPT0WU
LB771-HNC	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLzTWM2OD1{Mj60PFE{KM7:TR?=	MlTmV2FPT0WU
RT4	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDiTWM2OD1{Mz6zNlgzKM7:TR?=	MVvTRW5ITVJ?
NCI-H82	NI\JdJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4q3ZmlEPTB;MkOuOVUzPiEQvF2=	MYfTRW5ITVJ?
NCI-H524	M1r1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXoTWM2OD1{ND6zPFEzKM7:TR?=	M4X2U3NCVkeHUh?=
SNU-C1	MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fKU2lEPTB;MkSuPVExPSEQvF2=	NEDCOJhUSU6JRWK=
NCI-SNU-16	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LvWmlEPTB;NEiuN\|E1OiEQvF2=	M321dXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ALK / ALK / p-AKT / AKT / p-ERK / ERK / TβRI / TβRII; PubMed: 23993685 Mol Oncol Cells were treated with or without the indicated doses of 17-DMAG or AUY-922 for 3 h. Changes in ALK-related signaling and TGF-b receptors were analyzed using Western blot analysis. The densitometry values were determined relative to control of H2228 after normalization to b-actin protein. E-cadherin / Cleaved PARP / Bim; PubMed: 23993685 Mol Oncol Cells were treated with crizotinib (1 mM), 17-DMAG (1 mM), or AUY-922 (1 mM) for the indicated times. Cell lysates were subjected to Western blot analysis using the indicated antibodies. The densitometry values were determined relative to control after normalization to b-actin protein. HSP70 / Grp94 / Grp78 / p-eIF2α / CHOP / IRE1α / p-JNK; PubMed: 24796583 Oncotarget CCA cells were incubated with 0.5 uM NVP-AUY922 for 0, 2, 4, 8, 16, and 24 h. Whole cell lysates were subjected to western blot analysis for HSP70, Grp94, Grp78, p-eIF2α, CHOP, IRE1α, and phosphor-JNK. β-Actin was used as the loading control. CDK4 / HMGA2 ; PubMed: 26893968 PeerJ HCT116 cells were treated with NVP-AUY922 at the indicated concentrations for 48 hours. Cell extracts were analyzed using Western blotting with the antibodies for CDK4, Hsp70, and HMGA2, respectively.	23993685 24796583 26893968
Growth inhibition assay	Cell viability; PubMed: 26893968 PeerJ Cell viability assay was performed to determine the of HCT116 cells treated with various concentrations of NVP-AUY922 for 48 hours. p < 0.05, p < 0.01, **p < 0.001. All experiments were performed in three independent experiments.	26893968

In vivo

Treatment with NVP-AUY922 causes a robust antitumor response and inhibits p-Akt and VEGF expression in an HSC-2 xenograft model. ^[2] In BT474, NVP-AUY922 shows complete loss of ERBB2 and substantial depletion of ERα, in addition to reductions in CDK4 and phospho-ERK1/2. ^[3]

Protocol

Kinase Assay:^[3]	- Collapse Kinase assay: NVP-AUY922 is dissolved in DMSO at a concentration of 10 mM. NVP-AUY922 is assessed against HSP90α, HSP90β, GRP94, TRAP-1, HSP72, and topoisomerase II. Profiling against a panel of kinases has been carried out and screening against a panel of additional enzymes and receptors is performed at Cerep.
Cell Research:^[1]	- Collapse Cell lines: Human gastric cancer cells NCI-N87 Concentrations: 1 μM Incubation Time: 3 days Method: Human gastric cancer cells NCI-N87 (5-7 ×10³ in 50 μL/well) are seeded in 96-well plates and incubated at 37 °C for 24 hours, followed by NVP-AUY922 treatment for 1-3 days at 37 °C. After treatment, the cells are assayed by MTT method and analyzed by microplate reader. (Only for Reference)
Animal Research:^[3]	- Collapse Animal Models: Female NCr athymic mice bearing WM266.4 human melanoma xenografts Dosages: 50 mg/kg Administration: Administered via i.v. or i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	93 mg/mL warmed (199.76 mM)
	Water	Insoluble
	Ethanol	''31 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% DMSO+30% polyethylene glycol+1% Tween 80 For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Luminespib (NVP-AUY922) SDF

Molecular Weight	465.54
Formula	C₂₆H₃₁N₃O₅
CAS No.	747412-49-3
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	AUY-922
Smiles	CCNC(=O)C1=NOC(=C1C2=CC=C(CN3CCOCC3)C=C2)C4=CC(=C(O)C=C4O)C(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01772797	Completed	Drug: LDK378\|Drug: AUY922	Anaplastic Lymphoma Kinase (ALK)\|Non-small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	June 2013	Phase 1
NCT01752400	Completed	Drug: AUY922	Non Small Cell Lung Cancer	Massachusetts General Hospital	January 2013	Phase 2
NCT01613950	Completed	Drug: AUY922\|Drug: BYL719	Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein	Novartis Pharmaceuticals\|Novartis	December 2012	Phase 1
NCT01484860	Terminated	Drug: AUY922	Adenocarcinoma of the Pancreas\|Metastatic Disease	University Health Network Toronto\|Novartis Pharmaceuticals	January 2012	Phase 2
NCT01402401	Terminated	Drug: AUY922 + Trastuzumab	Advanced Gastric Cancer	Novartis Pharmaceuticals\|Novartis	November 2011	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

HSP (HSP90) Signaling Pathway Map

HSP (HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-AAG (Tanespimycin) : Phase III for Gastrointestinal Stromal Tumors.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (HSP90) Products

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90. VER155008 inhibits autophagy and causes reduced levels of HSP90 client proteins.
Tanespimycin (17-AAG)

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy. Phase 2.

Features:Displays very low toxicity toward normal cells.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association. Geldanamycin attenuates virus infection-induced ALI (acute lung injury)/ARDS (acute respiratory distress syndrome) by reducing the host's inflammatory responses.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM. NVP-HSP990 induces cell cycle arrest and apoptosis.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Luminespib (NVP-AUY922)